Aurimed - Company finances
|
EUR
|
2023
From: 2023-03-15
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|
|
Financial data
|
|||
| Sales revenue | 400 | 22,035 | 27,830 |
| Profit before tax | -9,936 | 14,250 | 19,389 |
| Net profit | -9,936 | 14,034 | 18,238 |
| Equity | -9,836 | 4,198 | 18,757 |
| Liabilities | 25,879 | 12,434 | 1,613 |
| Non-current assets | 12,600 | 10,080 | 11,477 |
| Current assets | 3,443 | 6,552 | 8,893 |
| Total assets | 16,043 | 16,632 | 20,370 |
|
Taxes paid
|
|||
| STI taxes | 147 | 67 | 296 |
|
Financial indicators
|
|||
| Revenue change y/y | - | +5408.8% | +26.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -61.9% | 84.4% | 89.5% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 334.3% | 97.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -2484.0% | 63.7% | 65.5% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -2484.0% | 64.7% | 69.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 3.0 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Aurimed - Social security debts
The company had no debts to Sodra
Aurimed - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Aurimed, MB (code 306273293) is a Lithuanian small partnership engaged in medical specialists activities. In 2025, the company generated revenue of EUR 27.8K and net profit of EUR 18.2K, with a profit margin of 65.5%. Performance improved from 2024, when revenue was EUR 22.0K and net profit EUR 14.0K, and it was far stronger than in 2023, when revenue was only EUR 400 and the company recorded a net loss of EUR 9.9K. The latest year therefore shows a clear continuation of growth in both turnover and profitability.
The balance sheet also strengthened in 2025. Total assets reached EUR 20.4K, equity rose to EUR 18.8K, and liabilities decreased to EUR 1.6K. This produced an equity ratio of 92.1% and a debt-to-equity ratio of 0.09. Return on equity was 97.2% and return on assets 89.5%, while asset turnover stood at 1.37x. Overall, the 2025 figures indicate a small but highly profitable business with a strong capital structure and improving financial position.
The balance sheet also strengthened in 2025. Total assets reached EUR 20.4K, equity rose to EUR 18.8K, and liabilities decreased to EUR 1.6K. This produced an equity ratio of 92.1% and a debt-to-equity ratio of 0.09. Return on equity was 97.2% and return on assets 89.5%, while asset turnover stood at 1.37x. Overall, the 2025 figures indicate a small but highly profitable business with a strong capital structure and improving financial position.